Fax: (617) 264-5242
Salvage radiation in men after prostate-specific antigen failure and the risk of death†
Article first published online: 22 MAR 2011
Copyright © 2011 American Cancer Society
Volume 117, Issue 17, pages 3925–3932, 1 September 2011
How to Cite
Cotter, S. E., Chen, M. H., Moul, J. W., Lee, W. R., Koontz, B. F., Anscher, M. S., Robertson, C. N., Walther, P. J., Polascik, T. J. and D'Amico, A. V. (2011), Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer, 117: 3925–3932. doi: 10.1002/cncr.25993
Dr. Chen had full access to all data in the study, and Drs. Cotter and D'Amico take responsibility for the integrity of the data and the accuracy of the data analysis.
- Issue published online: 19 AUG 2011
- Article first published online: 22 MAR 2011
- Manuscript Accepted: 3 JAN 2011
- Manuscript Revised: 14 DEC 2010
- Manuscript Received: 28 SEP 2010
- prostate cancer;
- radiation therapy;
- radical prostatectomy
A survival benefit has been observed with salvage radiation therapy (RT) for prostate-specific antigen (PSA) failure after radical prostatectomy (RP) in men with rapid rises in PSA doubling time (DT, <6 months). Whether such a benefit exits in men with a protracted PSA rise in DT (≥6 months) is unclear and was examined in the current study.
Of 4036 men who underwent RP at Duke University between 1988 and 2008, 519 experienced a PSA failure, had complete data, and were the subjects of this study. Univariate and multivariate Cox regression analyses were performed to evaluate whether salvage RT in men with either a rapid (<6 months) or a protracted (≥6 months) PSA DT was associated with the risk of all-cause mortality adjusting for age at the time of PSA failure, known prostate cancer prognostic factors, and cardiac comorbidity.
After a median follow-up of 11.3 years after PSA failure, 195 men died. Salvage RT was associated with a significant reduction in all-cause mortality for men with either a PSA DT of <6 months (adjusted hazard ratio [AHR], 0.53; P = .02) or a PSA DT of ≥6 months (AHR, 0.52; P = .003). In a subset of patients with comorbidity data at the time of PSA failure, salvage RT remained associated with a significant reduction in all-cause mortality for both men with a PSA DT of <6 months (AHR, 0.35; P = .042) or a PSA DT of ≥6 months (AHR, 0.60; P = .04).
Salvage RT for PSA DTs less than or in excess of 6 months is associated with a decreased risk in all-cause mortality. Cancer 2011. © 2011 American Cancer Society.